This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: ##STR00001## wherein R.sup.3 is optionally substituted aryl or heteroaryl, R.sup.1 and R.sup.2 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.